• November 16, 2017

For some time, researchers have been investigating the possibility that certain lung diseases, including inheritable conditions like cystic fibrosis (CF) and malignancies such as carcinomas, could potentially respond to gene therapy delivered directly to the lung. Studies have already shown some success in correcting genetic defects. Pulmonary delivery of DNA could also provide an effective […]

  • November 1, 2017

Spray pattern and plume geometry have long been established as required tests for orally inhaled and nasal drug product (OINDP) characterization. Furthermore, these tests are important indicators of aerosolization, spray performance and subsequent bioavailability (BA) of the delivered drug.

This article focuses on APSD determinations with the purpose of identifying potential pitfalls in set-up, execution and analysis that could obscure the findings, and therefore the interpretation of data, that are derived from such measurements.

Many patients, particularly the very young, the elderly and those with co-morbidities affecting coordination, need to use a facemask rather than a mouthpiece in order to receive inhaled medication via a pressurized metered dose inhaler with valved holding chamber (pMDI-VHC). This article explores the steps taken to design a range of facemasks that are age-of-user-appropriate. […]

Over the last 20 years, inhalation drug delivery has been adjusting to the phase out of chlorofluorocarbon (CFC) propellants. Following the signature of the Montreal Protocol on September 16, 1987, there has been a rush to re-formulate pressure metered dose inhalers (pMDIs) using alternative propellant systems. This has led to the advent of dry powder […]